V503
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cervical Cancers
Conditions
Cervical Cancers, Vulvar Cancer, Vaginal Cancer, Genital Lesions, PAP Test Abnormalities, HPV Infections
Trial Timeline
Aug 27, 2009 → Apr 22, 2021
NCT ID
NCT00943722About V503
V503 is a phase 3 stage product being developed by Merck for Cervical Cancers. The current trial status is completed. This product is registered under clinical trial identifier NCT00943722. Target conditions include Cervical Cancers, Vulvar Cancer, Vaginal Cancer.
What happened to similar drugs?
8 of 20 similar drugs in Cervical Cancers were approved
Approved (8) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04635423 | Phase 3 | Completed |
| NCT03903562 | Phase 3 | Completed |
| NCT03158220 | Phase 3 | Completed |
| NCT01254643 | Phase 3 | Completed |
| NCT00943722 | Phase 3 | Completed |
Competing Products
20 competing products in Cervical Cancers